HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AS2553627

structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - AS2553627: 3
  - Piperidines: 17
    - AS2553627: 3

Experts

1.	Hirose, Jun: 3 articles (11/2018 - 02/2017)
2.	Inami, Masamichi: 3 articles (11/2018 - 02/2017)
3.	Morokata, Tatsuaki: 3 articles (11/2018 - 02/2017)
4.	Nakamura, Koji: 3 articles (11/2018 - 02/2017)
5.	Noto, Takahisa: 3 articles (11/2018 - 02/2017)
6.	Fukahori, Hidehiko: 2 articles (11/2018 - 01/2018)
7.	Maeda, Masashi: 2 articles (11/2018 - 01/2018)
8.	Morio, Hiroki: 2 articles (11/2018 - 02/2017)
9.	Nakanishi, Tomonori: 2 articles (11/2018 - 01/2018)
10.	Ito, Misato: 2 articles (01/2018 - 02/2017)

Related Diseases

1.	Fibrosis (Cirrhosis) 11/01/2018 - "All AS2553627/TAC-treated monkeys surviving >90 days exhibited less interstitial fibrosis/tubular atrophy than monkeys in the MMF/TAC group. " 02/05/2017 - "In combination with tacrolimus, AS2553627 significantly reduced cardiac allograft vasculopathy and fibrosis that tacrolimus alone did not inhibit. " 01/01/2018 - "In addition, upregulation of cell surface markers, fibrosis/epithelial-mesenchymal transition and inflammation-related genes were reduced by the combination of AS2553672 and TAC, particularly CD8 and IL-6 mRNAs, indicating that AS2553627 prevented cell infiltration and inflammation in renal allografts. "
2.	Vasculitis (Vasculitides) 11/01/2018 - "Histopathological analysis revealed that acute T cell-mediated rejection events such as vasculitis and interstitial mononuclear cell infiltration were significantly inhibited in AS2553627/TAC-treated allografts compared with MMF/TAC-treated allografts. "
3.	Inflammation (Inflammations) 01/01/2018 - "In addition, upregulation of cell surface markers, fibrosis/epithelial-mesenchymal transition and inflammation-related genes were reduced by the combination of AS2553672 and TAC, particularly CD8 and IL-6 mRNAs, indicating that AS2553627 prevented cell infiltration and inflammation in renal allografts. "
4.	Atrophy 11/01/2018 - "All AS2553627/TAC-treated monkeys surviving >90 days exhibited less interstitial fibrosis/tubular atrophy than monkeys in the MMF/TAC group. "
5.	Anemia 02/05/2017 - "AS2553627 at the effective dose in rat transplantation models did not significantly reduce reticulocyte counts in peripheral whole blood after in vivo erythropoietin administration, indicating a low risk for anemia. "

Related Drugs and Biologics

1.	Tacrolimus (Prograf)
2.	Interleukin-6 (Interleukin 6)
3.	Erythropoietin

Related Therapies and Procedures

1.	Transplantation